Cardiac disease in cancer patients: An overview

Progress in Cardiovascular Diseases

Volumn 53, Issue 2, 2010, Pages 80-87

  Mann, Douglas L ^a   Krone, Ronald J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DALTEPARIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PRASUGREL; PROTEIN TYROSINE KINASE INHIBITOR; SIMVASTATIN; SPIRONOLACTONE; THIENOPYRIDINE DERIVATIVE; TRASTUZUMAB; WARFARIN; CARDIOVASCULAR AGENT;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; BLEEDING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOLOGIST; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVERSION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; DIAGNOSTIC TEST; DRUG ELUTING STENT; DRUG METABOLISM; EDITORIAL; EVIDENCE BASED MEDICINE; HEART ASSIST DEVICE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HEART FUNCTION TEST; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART TAMPONADE; HUMAN; HYPERTENSION; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; MEDICAL CARE; MEDICAL SPECIALIST; MORTALITY; PAIN; PERICARDIOCENTESIS; QT PROLONGATION; QUALITY OF LIFE; SURVIVAL TIME; THROMBOEMBOLISM; THROMBOSIS; CHEMICALLY INDUCED; COMPLICATION; DRUG INTERACTION; HEART DISEASES; NEOPLASMS; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK FACTOR;

ANTINEOPLASTIC AGENTS; CARDIOVASCULAR AGENTS; DRUG INTERACTIONS; HEART DISEASES; HUMANS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS;

EID: 77955858325     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2010.05.004     Document Type: Editorial

References (64)

1. Hampton T. Cancer therapy can be hard on the heart: researchers aim to explain-and avoid-cardiotoxicity. JAMA 2010, 303:1019-1020.
2. Albini A., Pennesi G., Donatelli F., et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010, 102:14-25.
3. Schmidinger M., Zielinski C.C., Vogl U.M., et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008, 26:5204-5212.
4. Force T., Krause D.S., Van Etten R.A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007, 7:332-344.
5. Sereno M., Brunello A., Chiappori A., et al. Cardiac toxicity: old and new issues in anti-cancer drugs. Clin Transl Oncol 2008, 10:35-46.
6. Hanrahan E.O., Gonzalez-Angulo A.M., Giordano S.H., et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 2007, 25:4952-4960.
7. Lenihan D.J., Esteva F.J. Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer. Oncologist 2008, 13:1224-1234.
8. Lenihan D.J. Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?. J Clin Oncol 2008, 26:5154-5155.
9. Dolci A., Dominici R., Cardinale D., et al. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity. Am J Clin Pathol 2008, 130:688-695.
10. Garg R., Yusuf S., et al. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995, 273:1450-1456. Collaborative Group on ACE Inhibitor Trials.
11. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009, 360:2503-2515. Bari 2D Study Group.
12. Killip T., Passamani E., Davis K. Coronary artery surgery study (CASS): a randomized trial of coronary bypass surgery. Eight years follow-up and survival in patients with reduced ejection fraction. Circulation 1985, 72:V102-V109.
13. Chaitman B.R., Ryan T.J., Kronmal R.A., et al. Coronary Artery Surgery Study (CASS): comparability of 10 year survival in randomized and randomizable patients. J Am Coll Cardiol 1990, 16:1071-1078.
14. Popat S., Smith I.E. Therapy insight: anthracyclines and trastuzumab-the optimal management of cardiotoxic side effects. Nat Clin Prac Oncol 2008, 5:324-335.
15. Koyama J., Ray-Sequin P.A., Falk R.H. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 2003, 107:2446-2452.
16. Guarneri V., Lenihan D.J., Valero V., et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006, 24:4107-4115.
17. Dibbs Z., Kurrelmeyer K., Kalra D., et al. Cytokines in heart failure: pathogenetic mechanisms and potential treatment. Proc Assoc Am Physicians 1999, 111:423-428.
18. Mann D.L., Young J.B. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest 1994, 105:897-904.
19. Tamariz L., Hare J.M. Inflammatory cytokines in heart failure: roles in aetiology and utility as biomarkers. Eur Heart J 2010, 31:768-770.
20. Yan A.T., Yan R.T., Cushman M., et al. Relationship of interleukin-6 with regional and global left-ventricular function in asymptomatic individuals without clinical cardiovascular disease: insights from the Multi-Ethnic Study of Atherosclerosis. Eur Heart J 2010, 31:875-882.
21. Godkar D, Bachu K, Dave B, et al. Comparison and co-relation of invasive and noninvasive methods of ejection fraction measurement. J Natl Med Assoc 2007;99:1227-1228, 31-34.
22. Hogg K., Swedberg K., McMurray J. Heart failure with preserved left ventricular systolic function: epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004, 43:317-327.
23. Hernandez A.F., Hammill B.G., O'Connor C.M., et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 2009, 53:184-192.
24. Vitarelli A., Tiukinhoy S., Di Luzio S., et al. The role of echocardiography in the diagnosis and management of heart failure. Heart Fail Rev 2003, 8:181-189.
25. Thygesen K., Alpert J.S., White H.D. Universal definition of myocardial infarction. J Am Coll Cardiol 2007, 50:2173-2195.
26. Kelley W.E., Januzzi J.L., Christenson R.H. Increases of cardiac troponin in conditions other than acute coronary syndrome and heart failure. Clin Chem 2009, 55:2098-2112.
27. Hunt S.A., Abraham W.T., Chin M.H., et al. Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009, 53:e1-e90.
28. de Lemos J.A., Mcguire D.K., Drazner M.H. B-type natriuretic peptide in cardiovascular disease. Lancet 2003, 362:316-322.
29. Cil T., Kaplan A.M., Altintas A., et al. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series. Clin Drug Investig 2009, 29:131-137.
30. Burjonroppa S.C., Tong A.T., Xiao L.C., et al. Cancer patients with markedly elevated B-type natriuretic peptide may not have volume overload. Am J Clin Oncol 2007, 30:287-293.
31. Mann D.L., Bristow M.R. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 2005, 111:2837-2849.
32. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
33. Delyani J.A. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int 2000, 57:1408-1411.
34. Pitt B. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Mol Cell Biol 2004, 217:53-58.
35. Tornio A., Pasanen M.K., Laitila J., et al. Comparison of 3-hydroxy-3-methylglutaryl coenzyme a (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. Basic Clin Pharmacol Toxicol 2005, 97:104-108.
36. Karp I., Behlouli H., Lelorier J., et al. Statins and cancer risk. Am J Med 2008, 121:302-309.
37. Goldstein M.R., Mascitelli L. Do statins decrease cardiovascular disease at the expense of increasing cancer?. Int J Cardiol 2009, 133:254-255.
38. Khaidakov M., Wang W., Khan J.A., et al. Statins and angiogenesis: is it about connections?. Biochem Biophys Res Commun 2009, 387:543-547.
39. Yang X., So W.Y., Ma R.C., et al. Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes Care 2009, 32:1826-1832.
40. Singh H., Mahmud S.M., Turner D., et al. Long-term use of statins and risk of colorectal cancer: a population-based study. Am J Gastroenterol 2009, 104:3015-3023.
41. Bil J., Zapala L., Nowis D., et al. Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro. Cancer Lett 2010, 288:57-67.
42. Elewa H.F., El-Remessy A.B., Somanath P.R., et al. Diverse effects of statins on angiogenesis: new therapeutic avenues. Pharmacotherapy 2010, 30:169-176.
43. Gonyeau M.J., Yuen D.W. A clinical review of statins and cancer: helpful or harmful?. Pharmacotherapy 2010, 30:177-194.
44. Bertagnolli M.M., Hsu M., Hawk E.T., et al. Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial. Cancer Prev Res 2010, 3:588-596.
45. Mehta N.G., Mehta M. Overcoming multidrug-resistance in cancer: statins offer a logical candidate. Med Hypotheses 2010, 74:237-239.
46. Jakobisiak M., Golab J. Statins can modulate effectiveness of antitumor therapeutic modalities. Med Res Rev 2010, 30:102-135.
47. Khemasuwan D., Divietro M.L., Tangdhanakanond K., et al. Statins decrease the occurrence of venous thromboembolism in patients with cancer. Am J Med 2010, 123:60-65.
48. Couzin J. Drug safety: FDA panel urges caution on many anti-inflammatory drugs. Science 2005, 307:1183a-5183a.
49. Borer J.S., Pouleur H., Abadie E., et al. Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. Eur Heart J 2007, 28:1904-1909.
50. Serebruany V.L. Aggressive chronic platelet inhibition with prasugrel and increased cancer risks: revising oral antiplatelet regimens?. Fundam Clin Pharmacol 2009, 23:411-417.
51. Powe D.G., Voss M.J., Habashy H.O., et al. Beta-blocker treatment is associated with a reduction in tumour metastasis and an improvement in specific survival in patients with breast cancer. Supplements Eur J Cancer 2010, 8:188. Presented at 7th European Breast Cancer Conference, Barcelona, Spain, March 2010.
52. "The Bypass Angioplasty Revascularization Investigation Investigators". Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996, 335:217-225.
53. King S.B., Smith S.C., Hirshfeld J.W., et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. J Am Coll Cardiol 2008, 51:172-209.
54. Fleisher L.A., Beckman J.A., Brown K.A., et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2007, 116:e418-e499.
55. McFadden E.P., Stabile E., Regar E., et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004, 364:1519-1521.
56. Heir J.S., Gottumukkala V., Singh M., et al. Coronary stents and noncardiac surgery: current clinical challenges and conundrums. Prev Cardiol 2010, 13:8-13.
57. Jaffe A.S., Babuin L., Apple F.S. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol 2006, 48:1-11.
58. Noble S.I., Shelley M.D., Coles B., et al. Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. Lancet Oncol 2008, 9:577-584.
59. Lee A.Y.Y., Levine M.N., Baker R.I., et al. Low-molecular-weight Heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003, 349:146-153.
60. Maisch B., Seferovic P.M., Ristic A.D., et al. Guidelines on the diagnosis and management of pericardial diseases executive summary: the Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2004, 25:587-610.
61. Tsang T.S., Freeman W.K., Sinak L.J., et al. Echocardiographically guided pericardiocentesis: evolution and state-of-the-art technique. Mayo Clin Proc 1998, 73:647-652.
62. Tsang T.S.M., Enriquez-Sarano M., Freeman W.K., et al. Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses: clinical profile, practice patterns, and outcomes spanning 21 years. Mayo Clin Proc 2002, 77:429-436.
63. Hidalgo J.D., Krone R., Rich M.W., et al. Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplant 2004, 34:615-619.
64. Khakoo A.Y., Kassiotis C.M., Tannir N., et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008, 112:2500-2508.